[Atropine eye drop 0.5% 10ml/bot 硫酸阿托品 點眼液 ] - [Atropine 0.5% ] 藥師 藥劑部藥師 發佈日期 2011/10/10 <藥物效用> 眼睛散瞳 <服藥指示> 1.請依照醫師的指示，絕對不可自行停藥或更改劑量。 2.盡可能保持每日於相同時間服藥。忘記服藥時，只要服用下次的藥。不可一 次服用兩次的藥量。 <注意事項> 1.中文名稱：硫酸阿托品點眼液。 <其他注意事項> 1.若您計畫(已)懷孕、哺乳，請告知您的醫(藥)師。 2.如果您對本藥成分過敏，請告知您的醫(藥)師。 3.服用此藥時，應該主動告知您的醫(藥)師所有您同時服用的其他藥物〈包含 處方藥、非處方藥及中藥〉。 <副作用> 1.每一種藥都有副作用，若有以下情況，請勿太驚慌： 2.上述症狀若持續且加重，請立刻聯絡您的醫師。 <藥品外觀> 紅色瓶裝 健康文章內文主要提供民眾降低對疾病因不了解產生之不安和恐懼，但不可 取代實際的醫療行為，所以身體如有不適請您前往醫院就醫治療。
Atropine eye drop 0.5% 10mlbot 硫酸阿托品 點眼液
1
0
0
Tam metin
Benzer Belgeler
北海道大學學系的學制方面與本系相近，都是 3
Objectives: The aim of this study was to evaluate clinical outcomes related to the protection of corneal endothelial cells and the safety of the Bio-Hyalur CS (Biotech
In the current body of literature, several studies have reported similar results for ocular hemodynamic changes, such as lower blood velocity and higher peripheric vascular
Most studies have reported no signif- icant difference in Schirmer test (ST) results, but decreased tear breakup time (TBUT) results in pterygium patients compared to healthy
Minimal pigment loss was seen in 5 patients, but the cosmetic results were satisfactory and no secondary surgical procedure was required.. Pigment leakage underneath the
In conclusion, the results of current study indicated that both recession and myectomy procedures are effective options for surgical treatment of primary inferior oblique
High recurrence rates of CFT elevation after the IDI injection observed in the present study are not surprising because the target popula- tion included only patients with
This is a case report of a 6-year-old female who devel- oped sterile corneal infiltrates after accelerated corneal crosslinking (CXL) treatment for keratoconus..
